Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia

93Citations
Citations of this article
186Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cancer cachexia is characterised by a progressive loss of muscle, resulting in functional impairment and shorter survival. Eicosapentaenoic acid, an n-3 polyunsaturated fatty acid found in fish, has been studied for its role as an anti-cachexia therapy. Initial results of eicosapentaenoic supplementation in advanced cancer were promising with improvements in lean body mass (LBM), appetite and quality of life. However, subsequent larger phase III clinical trials reported minimal benefits of supplementation. Recently, several studies have used different study designs, which may provide insight on the effectiveness of eicosapentaenoic in cancer cachexia and also on potential sources of divergent results in previous trials. This review examines the potential benefit of eicosapentaenoic supplementation on LBM and discusses limitations with current studies to identify methods which may aid in progressing the research of future clinical trials. © 2011 Cancer Research UK All rights reserved.

Cite

CITATION STYLE

APA

Murphy, R. A., Yeung, E., Mazurak, V. C., & Mourtzakis, M. (2011, November 8). Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. British Journal of Cancer. https://doi.org/10.1038/bjc.2011.391

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free